Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

Endometrial cancer is the most commonly diagnosed gynaecological malignancy. Unfortunately, 15–20% of women demonstrate persistent or recurrent tumours that are refractory to current chemotherapies. We previously identified activating mutations in fibroblast growth factor receptor 2 (FGFR2) in 12% (...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Packer, Leisl M., Stehbens, Samantha J., Bonazzi, Vanessa F., Gunter, Jennifer H., Ju, Robert J., Ward, Micheal, Gartside, Michael G., Byron, Sara A., Pollock, Pamela M.
Aineistotyyppi: Online Artikkeli Teksti
Kieli:English
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Research Articles
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441928/
https://www.ncbi.nlm.nih.gov/pubmed/30537101
http://dx.doi.org/10.1002/1878-0261.12422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441928/
https://www.ncbi.nlm.nih.gov/pubmed/30537101
http://dx.doi.org/10.1002/1878-0261.12422

Samankaltaisia teoksia